Akorn, Inc. / Hi-Tech Pharmacal Co. Inc.

Specialty Generic Pharmaceuticals (Difficult-to-Manufacture Dosage Forms)

Disease Overview

This deal is not therapy-area specific; it consolidates US specialty generic manufacturing for difficult-to-formulate dosage forms (oral solutions/suspensions, topical creams/ointments, nasal sprays, otics, sterile ophthalmics). These niche dosage forms have historically had fewer ANDA filers and higher margins than standard solid-oral generics, making them an attractive subsegment for consolidators.

Competitive Landscape

The 2013 US specialty generics landscape was led by Mylan, Teva, Sandoz (Novartis), Watson/Actavis, and Sun Pharma's Taro subsidiary across solid orals, with niche dosage form leaders including Perrigo (OTC liquids), Bausch & Lomb and Alcon (ophthalmics), and Hospira (sterile injectables). Akorn entered the deal as a focused ophthalmic and injectable generic player; Hi-Tech brought oral liquids/suspensions, topical creams, nasal sprays, otics, and a branded OTC unit (Health Care Products) plus a small specialty Rx unit (ECR Pharmaceuticals). The combination created the third-largest US generic ophthalmic player and broadened the dosage form mix into oral liquids, topicals, nasals and otics — categories with structurally fewer competitors due to formulation complexity. Management projected ~$15-20M annual cost synergies and stated the deal would be ~40% accretive to 2013 non-GAAP adjusted EPS at full synergy run-rate. The deal mattered because it positioned Akorn against larger consolidators (Hikma's Bedford, Endo's Par, Impax) by stacking up niche-dosage-form ANDA capacity that is harder to replicate than tablet/capsule lines.